These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

575 related articles for article (PubMed ID: 25101887)

  • 1. Some gating potentiators, including VX-770, diminish ΔF508-CFTR functional expression.
    Veit G; Avramescu RG; Perdomo D; Phuan PW; Bagdany M; Apaja PM; Borot F; Szollosi D; Wu YS; Finkbeiner WE; Hegedus T; Verkman AS; Lukacs GL
    Sci Transl Med; 2014 Jul; 6(246):246ra97. PubMed ID: 25101887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potentiator ivacaftor abrogates pharmacological correction of ΔF508 CFTR in cystic fibrosis.
    Cholon DM; Quinney NL; Fulcher ML; Esther CR; Das J; Dokholyan NV; Randell SH; Boucher RC; Gentzsch M
    Sci Transl Med; 2014 Jul; 6(246):246ra96. PubMed ID: 25101886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770.
    Van Goor F; Hadida S; Grootenhuis PD; Burton B; Cao D; Neuberger T; Turnbull A; Singh A; Joubran J; Hazlewood A; Zhou J; McCartney J; Arumugam V; Decker C; Yang J; Young C; Olson ER; Wine JJ; Frizzell RA; Ashlock M; Negulescu P
    Proc Natl Acad Sci U S A; 2009 Nov; 106(44):18825-30. PubMed ID: 19846789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanistic Approaches to Improve Correction of the Most Common Disease-Causing Mutation in Cystic Fibrosis.
    Bali V; Lazrak A; Guroji P; Matalon S; Bebok Z
    PLoS One; 2016; 11(5):e0155882. PubMed ID: 27214033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutation-specific dual potentiators maximize rescue of CFTR gating mutants.
    Veit G; Da Fonte DF; Avramescu RG; Premchandar A; Bagdany M; Xu H; Bensinger D; Stubba D; Schmidt B; Matouk E; Lukacs GL
    J Cyst Fibros; 2020 Mar; 19(2):236-244. PubMed ID: 31678009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cystic fibrosis transmembrane conductance regulator (CFTR) potentiators protect G551D but not ΔF508 CFTR from thermal instability.
    Liu X; Dawson DC
    Biochemistry; 2014 Sep; 53(35):5613-8. PubMed ID: 25148434
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutation-specific downregulation of CFTR2 variants by gating potentiators.
    Avramescu RG; Kai Y; Xu H; Bidaud-Meynard A; Schnúr A; Frenkiel S; Matouk E; Veit G; Lukacs GL
    Hum Mol Genet; 2017 Dec; 26(24):4873-4885. PubMed ID: 29040544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allosteric folding correction of F508del and rare CFTR mutants by elexacaftor-tezacaftor-ivacaftor (Trikafta) combination.
    Veit G; Roldan A; Hancock MA; Da Fonte DF; Xu H; Hussein M; Frenkiel S; Matouk E; Velkov T; Lukacs GL
    JCI Insight; 2020 Sep; 5(18):. PubMed ID: 32853178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low free drug concentration prevents inhibition of F508del CFTR functional expression by the potentiator VX-770 (ivacaftor).
    Matthes E; Goepp J; Carlile GW; Luo Y; Dejgaard K; Billet A; Robert R; Thomas DY; Hanrahan JW
    Br J Pharmacol; 2016 Feb; 173(3):459-70. PubMed ID: 26492939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic Potentiation of Cystic Fibrosis Transmembrane Conductance Regulator Gating by Two Chemically Distinct Potentiators, Ivacaftor (VX-770) and 5-Nitro-2-(3-Phenylpropylamino) Benzoate.
    Lin WY; Sohma Y; Hwang TC
    Mol Pharmacol; 2016 Sep; 90(3):275-85. PubMed ID: 27413118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Restoration of R117H CFTR folding and function in human airway cells through combination treatment with VX-809 and VX-770.
    Gentzsch M; Ren HY; Houck SA; Quinney NL; Cholon DM; Sopha P; Chaudhry IG; Das J; Dokholyan NV; Randell SH; Cyr DM
    Am J Physiol Lung Cell Mol Physiol; 2016 Sep; 311(3):L550-9. PubMed ID: 27402691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergy-based small-molecule screen using a human lung epithelial cell line yields ΔF508-CFTR correctors that augment VX-809 maximal efficacy.
    Phuan PW; Veit G; Tan J; Roldan A; Finkbeiner WE; Lukacs GL; Verkman AS
    Mol Pharmacol; 2014 Jul; 86(1):42-51. PubMed ID: 24737137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination potentiator ('co-potentiator') therapy for CF caused by CFTR mutants, including N1303K, that are poorly responsive to single potentiators.
    Phuan PW; Son JH; Tan JA; Li C; Musante I; Zlock L; Nielson DW; Finkbeiner WE; Kurth MJ; Galietta LJ; Haggie PM; Verkman AS
    J Cyst Fibros; 2018 Sep; 17(5):595-606. PubMed ID: 29903467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural mechanisms for defective CFTR gating caused by the Q1412X mutation, a severe Class VI pathogenic mutation in cystic fibrosis.
    Yeh JT; Yu YC; Hwang TC
    J Physiol; 2019 Jan; 597(2):543-560. PubMed ID: 30408177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment.
    Pettit RS
    Ann Pharmacother; 2012; 46(7-8):1065-75. PubMed ID: 22739718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correctors and Potentiators Rescue Function of the Truncated W1282X-Cystic Fibrosis Transmembrane Regulator (CFTR) Translation Product.
    Haggie PM; Phuan PW; Tan JA; Xu H; Avramescu RG; Perdomo D; Zlock L; Nielson DW; Finkbeiner WE; Lukacs GL; Verkman AS
    J Biol Chem; 2017 Jan; 292(3):771-785. PubMed ID: 27895116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.
    Patel S; Sinha IP; Dwan K; Echevarria C; Schechter M; Southern KW
    Cochrane Database Syst Rev; 2015 Mar; (3):CD009841. PubMed ID: 25811419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanism-based corrector combination restores ΔF508-CFTR folding and function.
    Okiyoneda T; Veit G; Dekkers JF; Bagdany M; Soya N; Xu H; Roldan A; Verkman AS; Kurth M; Simon A; Hegedus T; Beekman JM; Lukacs GL
    Nat Chem Biol; 2013 Jul; 9(7):444-54. PubMed ID: 23666117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Probing conformational rescue induced by a chemical corrector of F508del-cystic fibrosis transmembrane conductance regulator (CFTR) mutant.
    Yu W; Kim Chiaw P; Bear CE
    J Biol Chem; 2011 Jul; 286(28):24714-25. PubMed ID: 21602569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ribosomal Stalk Protein Silencing Partially Corrects the ΔF508-CFTR Functional Expression Defect.
    Veit G; Oliver K; Apaja PM; Perdomo D; Bidaud-Meynard A; Lin ST; Guo J; Icyuz M; Sorscher EJ; Hartman JL; Lukacs GL
    PLoS Biol; 2016 May; 14(5):e1002462. PubMed ID: 27168400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.